Biomarkers and surrogate endpoints: How and when might they impact drug development?

Disease Markers

Volumn 18, Issue 2, 2002, Pages 83-90

  Lathia, Chetan D ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; COST; DECISION MAKING; DISEASE MARKER; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; HUMAN; HUMAN GENOME; MEASUREMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0036399227     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/438745     Document Type: Article

References (17)

1. A.J. Atkinson Jr., Physiological and laboratory markers of drug effect, in: Principles of Clinical Pharmacology, A.J. Atkinson Jr, C.E. Daniels, R.L. Dedrick, C. Grudzinskas and S.P. Markey, eds, New York: Academic, 2001.
2. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin. Pharmacol. Ther. 69 (2001), 89-95.
3. T.M. Bocan, B.R. Krause, W.S. Rosebury, S.B. Mueller, X. Lu, C. Dagle, T. Major, C. Lathia and H. Lee, The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits, Arterioscler Thromb Vasc Biol 20 (2000), 70-79.
4. A.V. Chobanian, The influence of hypertension and other hemodynamic factors in atherogenesis, Prog. Cardiovasc. Dis. 26 (1983), 177-196.
5. R. Corti, Z.A. Fayad, V. Fuster, S.G. Worthley, G. Helft, J. Chesebro, M. Mercuri and J.J. Badimon, Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging, Circulation 104 (2001), 249-252.
6. L. Deyton, Importance of surrogate markers in evaluation of antiviral therapy for HIV infection, JAMA 276 (1996), 159-160.
7. D.S. Echt, P.R. Liebson, B. Mitchell, R.W. Peters, D. Obias-Manno et al., Mortality and morbidity of patients receiving encainide, flecainide or placebo: the cardiac arrythmia suppression trial, N. Engl. J. Med. 324 (1991), 781-788.
8. Food Drug Admin. Cen. Drug Eval. Res., Cent. Biol. Eval. Res., Guidance for industry: Exposure-Response Relationships: Study Design, Data Analysis, and Regulatory Applications, 2002. http:/www.fda.gov/cder/guidances.
9. A.M. Gotto Jr, J.C. LaRosa, D Hunninghake, S.M. Grundy, P.W. Wilson et al, The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart Association and the National Heart, Lung, and Blood Institute, Circulation 81 (1990), 1721-1733.
10. G. Helft, S.G. Worthley, V. Fuster, Z.A. Fayad, A.G. Zaman, R. Corti, J.T. Fallon and J.J. Badimon, Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging, Circulation 105 (2002), 993-998.
11. L.J. Lesko and A.J. Atkinson Jr., Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies, Annu. Rev. Pharmacol. Toxicol. 41 (2001), 347-366.
12. I.C. Marschner, A.C. Collier, R.W. Coombs, R.T. D'Aquila, V. DeGruttola et al., Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy, J. Infect. Dis. 177 (1998), 40-47.
13. Physician's Desk Reference, Montvale, NJ: Med. Econ., 54th ed., 2002, pp. 1414-1417.
14. Physician's Desk Reference, Montvale, NJ, Med. Econ., 54th ed., 2002, pp. 2095-2102.
15. P.M. Ravdin, Should HER2 status be routinely measured for all breast cancer patients? Semin. Oncol. 26(Suppl. 12) (1999), 117-123.
16. B.L. Riggs, S.F. Hodgson, W.M. O'Fallon, E.Y.S. Chao, H.W. Wahner et al., Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis, N. Engl. J. Med. 322 (1990), 802-809.
17. B.D. Roth, C.J. Blankley, M.L. Hoefle, A. Holmes, W.H. Roark, B.K. Trivedi, A.D. Essenburg, D.A. Kieft, B.R. Krause and R.L. Stanfield, Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents, J. Med. Chem. 35 (1992), 1609-1617.